Parexel named Best Contract Research Organisation
Uxbridge-based Parexel, one of the world’s largest Clinical Research Organisations (CROs) providing the full range of Phase I to IV clinical development services, has been named Best Contract Research Organisation at the 17th Annual Vaccine Industry Excellence Awards. Winners were named across 13 categories, including Best Contract Research Organisation, which recognises the role of CROs in supporting the development of safe and effective vaccines.
“We are honoured to be recognised with this year’s ViE Award for Best Contract Research Organisation,” said Amy McKee, MD, Chief Medical Officer & Head of Oncology Centre of Excellence. “This accomplishment reflects the depth of experience and commitment of our cross-functional infectious disease and vaccine experts and global delivery team to develop leading preventive and therapeutic vaccines that advance global health. We look forward to our continued collaboration with our biopharmaceutical customers in this important area to improve patient outcomes.”
Parexel was named from among eight CRO finalists. A distinguished industry advisory board selected the company based on its ability to: provide a range of services in niche and core therapeutic areas; demonstrate methods of performance improvement and introduction of new services; ensure attention to and quality of relationships with clients; reach milestones and final outcomes; and build and maintain existing and long-term partnerships.
Over the last five years Parexel has conducted more than 225 clinical projects in the infectious disease and vaccine therapeutic area involving more than 9,150 global sites. Parexel’s Infectious Disease and Franchise core team is led by Anne Kasmar, MD, MSc, Senior Vice President and Global Therapeutic Head of Infectious Disease and Vaccines, and is comprised of dedicated physicians and cross-functional colleagues.
Stay up to date with all ARC news on our social media.
